Sci Rep:磁力纳米靶向药物或将有效解决血栓问题

2016-06-25 佚名 生物谷

血栓造成血管堵塞会引起许多健康问题,甚至会带来生命威胁,缓解病情的一个主要目标就是有效地进行溶栓。为了实现这一目标,来自ITMO大学的科学家们开发了一种由磁力控制的药物,能够通过外部磁场将药物聚集在血栓部位,该药物能够通过静脉注射的方式安全进入体内,溶栓效果比普通的酶类药物更好。这项新成果还可以帮助降低溶栓药物的剂量,避免许多副作用的发生。相关研究结果发表在国际学术期刊Scientific


血栓造成血管堵塞会引起许多健康问题,甚至会带来生命威胁,缓解病情的一个主要目标就是有效地进行溶栓。为了实现这一目标,来自ITMO大学的科学家们开发了一种由磁力控制的药物,能够通过外部磁场将药物聚集在血栓部位,该药物能够通过静脉注射的方式安全进入体内,溶栓效果比普通的酶类药物更好。这项新成果还可以帮助降低溶栓药物的剂量,避免许多副作用的发生。相关研究结果发表在国际学术期刊Scientific Reports上。

在一些血栓导致的紧急情况下,血栓必须在短时间内被清除,一旦过了最佳治疗时间,组织会因得不到血流供应而发生死亡,但是即使病人足够幸运及时进行了溶栓治疗,还是可能会因为使用溶栓药物而出现大量副作用。溶栓药物面临的一大挑战在于不能靶向血栓,还会扩散到整个循环系统。

为了解决上述问题,研究人员决定开发一种靶向药物输送方法,从而能够帮助减少药物使用剂量,确保药物治疗效果集中在血栓部位。

因此研究人员合成了一种由多孔磁性框架和常用做溶栓成分的尿激酶分子组成的复合材料,这种材料能够用于制作纳米级别的可注射溶栓溶液,在外部磁场作用下轻松定位到血栓附近发挥溶栓作用。

更为重要的是,这种磁性框架还可以保护酶分子避免受到血液中各种抑制性分子的影响。文章第一作者Andrey Drozdov指出:“通常为了延长药物的作用时间,酶分子会包埋在聚合物基质中,逐渐从基质中释放出来,最终失去所有活性。与此相反,我们的实验结果表明受到磁性框架保护的酶分子在很长一段时间内都能够保持治疗活性,即使重复使用也仍然能够发挥作用,并且这种新药物的溶栓效果远远好于未受保护的酶类药物。”

研究人员认为在未来这种新药物不仅能够用于溶栓治疗,还可以用于预防血栓形成。他们已经着手准备进行更多的临床前研究,进一步确定这种新药的安全性和作用效果。

原始出处:

Drozdov AS, Vinogradov VV, Dudanov IP, Vinogradov VV.Leach-proof magnetic thrombolytic nanoparticles and coatings of enhanced activity.

Sci Rep. 2016 Jun 20;6:28119. doi: 10.1038/srep28119.



版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=91794, encodeId=4e4391e94a1, content=可以学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200609/ef6a57dbe7f1489dad7446b7c5217858/d5e4fe65996c4446a029b0f5d056abb1.jpg, createdBy=6b011518214, createdName=午夜星河, createdTime=Sat Jul 02 19:31:00 CST 2016, time=2016-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=91274, encodeId=b6af912e47a, content=靶向很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 27 07:58:00 CST 2016, time=2016-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=91275, encodeId=599e912e58a, content=的确不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 27 07:58:00 CST 2016, time=2016-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=91172, encodeId=320d911e2ab, content=好文章,值得收藏!, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEIsrUxHnicsiaqwzJibCks60HOicbEAgbNzUiciboMJDzsWg16OHTeNHhyYvTg6TDXTlOx7icnhttCYYe2ujYt0yND7dYusOsibl9XnQCE/0, createdBy=7ad21722200, createdName=jaysppr, createdTime=Sun Jun 26 14:46:00 CST 2016, time=2016-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=91153, encodeId=537091153e9, content=和我文章的图好像, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Sun Jun 26 11:30:00 CST 2016, time=2016-06-26, status=1, ipAttribution=)]
    2016-07-02 午夜星河

    可以学习学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=91794, encodeId=4e4391e94a1, content=可以学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200609/ef6a57dbe7f1489dad7446b7c5217858/d5e4fe65996c4446a029b0f5d056abb1.jpg, createdBy=6b011518214, createdName=午夜星河, createdTime=Sat Jul 02 19:31:00 CST 2016, time=2016-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=91274, encodeId=b6af912e47a, content=靶向很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 27 07:58:00 CST 2016, time=2016-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=91275, encodeId=599e912e58a, content=的确不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 27 07:58:00 CST 2016, time=2016-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=91172, encodeId=320d911e2ab, content=好文章,值得收藏!, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEIsrUxHnicsiaqwzJibCks60HOicbEAgbNzUiciboMJDzsWg16OHTeNHhyYvTg6TDXTlOx7icnhttCYYe2ujYt0yND7dYusOsibl9XnQCE/0, createdBy=7ad21722200, createdName=jaysppr, createdTime=Sun Jun 26 14:46:00 CST 2016, time=2016-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=91153, encodeId=537091153e9, content=和我文章的图好像, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Sun Jun 26 11:30:00 CST 2016, time=2016-06-26, status=1, ipAttribution=)]
    2016-06-27 milkshark

    靶向很好

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=91794, encodeId=4e4391e94a1, content=可以学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200609/ef6a57dbe7f1489dad7446b7c5217858/d5e4fe65996c4446a029b0f5d056abb1.jpg, createdBy=6b011518214, createdName=午夜星河, createdTime=Sat Jul 02 19:31:00 CST 2016, time=2016-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=91274, encodeId=b6af912e47a, content=靶向很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 27 07:58:00 CST 2016, time=2016-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=91275, encodeId=599e912e58a, content=的确不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 27 07:58:00 CST 2016, time=2016-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=91172, encodeId=320d911e2ab, content=好文章,值得收藏!, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEIsrUxHnicsiaqwzJibCks60HOicbEAgbNzUiciboMJDzsWg16OHTeNHhyYvTg6TDXTlOx7icnhttCYYe2ujYt0yND7dYusOsibl9XnQCE/0, createdBy=7ad21722200, createdName=jaysppr, createdTime=Sun Jun 26 14:46:00 CST 2016, time=2016-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=91153, encodeId=537091153e9, content=和我文章的图好像, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Sun Jun 26 11:30:00 CST 2016, time=2016-06-26, status=1, ipAttribution=)]
    2016-06-27 milkshark

    的确不错

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=91794, encodeId=4e4391e94a1, content=可以学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200609/ef6a57dbe7f1489dad7446b7c5217858/d5e4fe65996c4446a029b0f5d056abb1.jpg, createdBy=6b011518214, createdName=午夜星河, createdTime=Sat Jul 02 19:31:00 CST 2016, time=2016-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=91274, encodeId=b6af912e47a, content=靶向很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 27 07:58:00 CST 2016, time=2016-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=91275, encodeId=599e912e58a, content=的确不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 27 07:58:00 CST 2016, time=2016-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=91172, encodeId=320d911e2ab, content=好文章,值得收藏!, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEIsrUxHnicsiaqwzJibCks60HOicbEAgbNzUiciboMJDzsWg16OHTeNHhyYvTg6TDXTlOx7icnhttCYYe2ujYt0yND7dYusOsibl9XnQCE/0, createdBy=7ad21722200, createdName=jaysppr, createdTime=Sun Jun 26 14:46:00 CST 2016, time=2016-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=91153, encodeId=537091153e9, content=和我文章的图好像, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Sun Jun 26 11:30:00 CST 2016, time=2016-06-26, status=1, ipAttribution=)]
    2016-06-26 jaysppr

    好文章,值得收藏!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=91794, encodeId=4e4391e94a1, content=可以学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200609/ef6a57dbe7f1489dad7446b7c5217858/d5e4fe65996c4446a029b0f5d056abb1.jpg, createdBy=6b011518214, createdName=午夜星河, createdTime=Sat Jul 02 19:31:00 CST 2016, time=2016-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=91274, encodeId=b6af912e47a, content=靶向很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 27 07:58:00 CST 2016, time=2016-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=91275, encodeId=599e912e58a, content=的确不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Jun 27 07:58:00 CST 2016, time=2016-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=91172, encodeId=320d911e2ab, content=好文章,值得收藏!, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEIsrUxHnicsiaqwzJibCks60HOicbEAgbNzUiciboMJDzsWg16OHTeNHhyYvTg6TDXTlOx7icnhttCYYe2ujYt0yND7dYusOsibl9XnQCE/0, createdBy=7ad21722200, createdName=jaysppr, createdTime=Sun Jun 26 14:46:00 CST 2016, time=2016-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=91153, encodeId=537091153e9, content=和我文章的图好像, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Sun Jun 26 11:30:00 CST 2016, time=2016-06-26, status=1, ipAttribution=)]
    2016-06-26 xiaotaiyang1

    和我文章的图好像

    0

相关资讯

学者首次揭示血小板功能水平高易引发血栓疾病

“患者血小板功能水平与中、远期卒中及心梗发生存在密切的相关性。”这是我国学者经过两年多的辛勤努力,分别完成了对卒中患者和心梗PCI术后患者血小板功能与再发生血栓相关性两项大规模研究后得出的结论。这也是全球首次公布血小板功能与中、远期心梗和脑梗患者再发生存在密切相关性研究结果。 结果显示:血小板功能高的缺血性卒中(即脑梗)患者再发生缺血性卒中风险高达3.92%,而血小板功能低的患者无一发生血栓。而

Hosp Pediatr:肥胖是儿童VTE的危险因素

根据一个单一的机构研究的结果,肥胖可能是儿童静脉血栓栓塞症(VTE)的一个显着的危险因素。小儿VTE多重危险因素包括血液感染和住院时间延长等,虽然肥胖是成人VTE的危险因素,但是关于肥胖对儿童VTE风险的影响,既往研究得出了不一致的结论。此外,预防VTE的肥胖儿童需要增加依诺肝素的剂量。维克森林医学院的Elizabeth E. Halvorson博士和同事进行了一项回顾性病例对照研究,探究小儿的V

Br J Surg:急诊阑尾切除术后VTE发生风险高

阑尾炎是最常见的腹内急诊手术指征。研究者进行了一项研究,探究急诊阑尾切除术后症状性静脉血栓栓塞(VTE)的绝对和相对风险。与阑尾切除术前一年的基线VTE风险相比,使用泊松回归计算急诊阑尾切除术后VTE的初始发生率和调整后的发病率比(IRRs)。该研究共涉及了13441名急诊阑尾切除术的患者,其中有56名(0.4%)在术后第一年发生了VTE。住院期间VTE的绝对发生了最高,达91.29/1000人年

Cell:血栓也可传染?肠道微生物或是重要媒介

2016年3月16日讯 /生物谷BIOON/ --本文亮点: TMAO水平升高能够预测人类发生血栓的风险 TMAO能够增强刺激依赖性血小板的激活 饮食来源的胆碱,肠道微生物以及TMAO都与体内的血栓形成有关 微生物移植表明血栓形成具有可传播的特点 近日,来自美国克利夫兰的科学家们在国际学术期刊Cell上发表了一项最新研究进展,他们发现肠道微生物产生的代谢物TMAO能够影响血小板功能增

Hepatology:门脉血栓患者食管胃静脉曲张出血研究

食管胃底静脉曲张破裂出血常见于无肝硬化的门静脉血栓形成患者。肝硬化食管静脉曲张破裂出血的进展与肝硬化食管静脉曲张的发展相似。研究人员对来自巴塞罗那、西班牙、巴黎、法国的326名无肝硬化的慢性门静脉血栓(PVT)患者进行了研究,最终178名患者的数据纳入了分析,中位数随访49个月。15%的患者(n = 27)以食管静脉曲张破裂出血为首要表现,对其他患者的最初内窥镜检查显示34%的患者(n = 52)

Lancet Respir Med:利奥西呱治疗慢性血栓栓塞性肺动脉高压的安全性耐受性研究

近期有研究者发现,慢性血栓栓塞性肺动脉高压患者长期使用利奥西呱耐受性好,此外研究人员还发现了两个与治疗相关的预后因素。来自法国的研究者Gérald Simonneau博士和同事对CHEST-2开放研究中的237名参与者进行了研究,这些患者服用利奥西呱2年,每天3次,最大剂量2.5 mg。研究者分析了患者基线和随访3年的的6分钟步行距离(6MWD)、WHO功能分类、N末端脑钠肽激素原(NT-proB